Lucentis & Byooviz doses ordered for macular degeneration should be interchanged to Avastin.
Lucentis & Byooviz are classified as therapeutically equivalent for the FDA approved indications: macular degeneration and retinal vein occlusion if the need arises.
Lucentis is formulary restricted to retina surgeons for treatment of retinopathy of prematurity.
Reviewed: October 25, 2006 (Lucentis), July 2024 (Byooviz)
Lucentis & Byooviz doses ordered for macular degeneration should be interchanged to Avastin.
Lucentis & Byooviz are classified as therapeutically equivalent for the FDA approved indications: macular degeneration and retinal vein occlusion if the need arises.
Lucentis is formulary restricted to retina surgeons for treatment of retinopathy of prematurity.
Reviewed: October 25, 2006 (Lucentis), July 2024 (Byooviz)
Updated: 23 April 2019 (Lucentis)